Copy to clipboard 
ORTHOWORLD estimates Medtronic’s (MDT) FY3Q18 revenue at US $740.0MM, +1.4% vs. FY3Q17 (quarter ended 1/26/18), and calendar year 2017 revenue at US $2,966.0MM, +1.2% vs. CY2016.
| 4Q17 | 4Q16 | $ Change | % Change | |
| Spine | $605.0 | $601.0 | $4.0 | 0.7% |
| Orthobiologics | $135.0 | $129.0 | $6.0 | 4.7% |
| Total | $740.0 | $730.0 | $10.0 | 1.4% |
| 2017 | 2016 | $ Change | % Change | |
| Spine | $2,445.0 | $2,429.0 | $16.0 | 0.7% |
| Orthobiologics | $521.0 | $501.0 | $20.0 | 4.0% |
| Total | $2,966.0 | $2,930.0 | $36.0 | 1.2% |
Echoing quarters past, leadership cited growth drivers of the Prestige LP cervical disc and the continued success of Surgical Synergy, a strategy that combines surgical enabling tools (imaging, navigation, powered instruments, nerve monitoring and Mazor Robotics) with MDT’s spine implants. Also noted: strong growth momentum in China and Latin America, continued account penetration with the O-Arm, strong balloon kyphoplasty growth in Asia Pacific regions. bone morphogenetic protein is also performing well ex-U.S.—that strong growth offset declines in core spine.
On the Mazor relationship, their technology will be fully integrated into Medtronic’s spine enabling tools by January 2019.
A few minutes were spent on Medtronic Orthopedic Solutions at the end of the call, communicating that the company is still in early phases, taking a little longer than they thought, continuing to tweak the instrument design for the knee (which has been implanted in about 50 patients); the hip is only a few quarters out from its July 2017 FDA clearance—no further update on the progress of the latter.
Source: Medtronic plc, ORTHOWORLD estimates
ORTHOWORLD estimates Medtronic’s (MDT) FY3Q18 revenue at US $740.0MM, +1.4% vs. FY3Q17 (quarter ended 1/26/18), and calendar year 2017 revenue at US $2,966.0MM, +1.2% vs. CY2016.
Q17
Q16
$ Change
% Change
Spine
$605.0
$601.0
$4.0 ...
ORTHOWORLD estimates Medtronic’s (MDT) FY3Q18 revenue at US $740.0MM, +1.4% vs. FY3Q17 (quarter ended 1/26/18), and calendar year 2017 revenue at US $2,966.0MM, +1.2% vs. CY2016.
| 4Q17 | 4Q16 | $ Change | % Change | |
| Spine | $605.0 | $601.0 | $4.0 | 0.7% |
| Orthobiologics | $135.0 | $129.0 | $6.0 | 4.7% |
| Total | $740.0 | $730.0 | $10.0 | 1.4% |
| 2017 | 2016 | $ Change | % Change | |
| Spine | $2,445.0 | $2,429.0 | $16.0 | 0.7% |
| Orthobiologics | $521.0 | $501.0 | $20.0 | 4.0% |
| Total | $2,966.0 | $2,930.0 | $36.0 | 1.2% |
Echoing quarters past, leadership cited growth drivers of the Prestige LP cervical disc and the continued success of Surgical Synergy, a strategy that combines surgical enabling tools (imaging, navigation, powered instruments, nerve monitoring and Mazor Robotics) with MDT’s spine implants. Also noted: strong growth momentum in China and Latin America, continued account penetration with the O-Arm, strong balloon kyphoplasty growth in Asia Pacific regions. bone morphogenetic protein is also performing well ex-U.S.—that strong growth offset declines in core spine.
On the Mazor relationship, their technology will be fully integrated into Medtronic’s spine enabling tools by January 2019.
A few minutes were spent on Medtronic Orthopedic Solutions at the end of the call, communicating that the company is still in early phases, taking a little longer than they thought, continuing to tweak the instrument design for the knee (which has been implanted in about 50 patients); the hip is only a few quarters out from its July 2017 FDA clearance—no further update on the progress of the latter.
Source: Medtronic plc, ORTHOWORLD estimates
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
